{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:52:25Z","timestamp":1786114345285,"version":"build-2736575974"},"reference-count":70,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,5]],"date-time":"2027-08-05T00:00:00Z","timestamp":1817424000000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01HL169976"],"award-info":[{"award-number":["R01HL169976"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01HL159900"],"award-info":[{"award-number":["R01HL159900"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01HL170260"],"award-info":[{"award-number":["R01HL170260"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R21HL163720"],"award-info":[{"award-number":["R21HL163720"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.05.020","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:20:04Z","timestamp":1779812404000},"page":"4621-4634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vivo base editing of Asgr1 reduces blood lipids in mice"],"prefix":"10.1016","volume":"34","author":[{"given":"Gaurav","family":"Agrahari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuong Thi Kieu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Eugene","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8202-9186","authenticated-orcid":false,"given":"Renzhi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.05.020_bib1","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2026.05.020_bib2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.020_bib3","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2026.05.020_bib4","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.mcna.2017.03.001","article-title":"Statins for Primary Prevention of Cardiovascular Disease: Review of Evidence and Recommendations for Clinical Practice","volume":"101","author":"Kazi","year":"2017","journal-title":"Med. Clin. North. Am."},{"key":"10.1016\/j.ymthe.2026.05.020_bib6","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2026.05.020_bib7","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymthe.2026.05.020_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2026.05.020_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.020_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.020_bib11","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.020_bib12","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.numecd.2016.05.006","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons","volume":"26","author":"Yadav","year":"2016","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.ymthe.2026.05.020_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.595819","article-title":"PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects","volume":"11","author":"Katzmann","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib14","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib15","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.020_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","article-title":"The role of ANGPTL3 in controlling lipoprotein metabolism","volume":"52","author":"Tikka","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.ymthe.2026.05.020_bib17","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.3390\/ijms22147310","article-title":"Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia","volume":"22","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.05.020_bib18","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.molmet.2017.06.014","article-title":"ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase","volume":"6","author":"Chi","year":"2017","journal-title":"Mol. Metab."},{"key":"10.1016\/j.ymthe.2026.05.020_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/jcdd5030039","article-title":"Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects","volume":"5","author":"Lupo","year":"2018","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"10.1016\/j.ymthe.2026.05.020_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100112","article-title":"Angiopoietin-like 3 inhibition of endothelial lipase is not modulated by angiopoietin-like 8","volume":"62","author":"Sylvers-Davie","year":"2021","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymthe.2026.05.020_bib21","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 Deficiency and Protection Against Coronary Artery Disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib22","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40265-021-01516-y","article-title":"Evinacumab: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2026.05.020_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MOL.0000000000000395","article-title":"Asialoglycoprotein receptors as important mediators of plasma lipids and atherosclerosis","volume":"28","author":"Igdoura","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib24","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1073\/pnas.82.19.6465","article-title":"Sequence of a second human asialoglycoprotein receptor: conservation of two receptor genes during evolution","volume":"82","author":"Spiess","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.05.020_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0092-8674(83)90518-4","article-title":"Intracellular site of asialoglycoprotein receptor-ligand uncoupling: double-label immunoelectron microscopy during receptor-mediated endocytosis","volume":"32","author":"Geuze","year":"1983","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.05.020_bib26","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1056\/NEJMoa1508419","article-title":"Variant ASGR1 Associated with a Reduced Risk of Coronary Artery Disease","volume":"374","author":"Nioi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.020_bib27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41569-022-00768-9","article-title":"ASGR1 inhibition stimulates cholesterol excretion","volume":"19","author":"Huynh","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41586-022-05006-3","article-title":"Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion","volume":"608","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.020_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009891","article-title":"Deficiency of ASGR1 in pigs recapitulates reduced risk factor for cardiovascular disease in humans","volume":"17","author":"Xie","year":"2021","journal-title":"Plos Genet."},{"key":"10.1016\/j.ymthe.2026.05.020_bib30","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1161\/ATVBAHA.124.321076","article-title":"ASGR1 Deficiency Inhibits Atherosclerosis in Western Diet-Fed ApoE(-\/-) Mice by Regulating Lipoprotein Metabolism and Promoting Cholesterol Efflux","volume":"44","author":"Zhang","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.020_bib32","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities","volume":"19","author":"Porto","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.05.020_bib33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2217T to G\u2217C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.020_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aao4774","article-title":"Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity","volume":"3","author":"Komor","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2026.05.020_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13578-023-01036-0","article-title":"Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice","volume":"13","author":"Zuo","year":"2023","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ymthe.2026.05.020_bib36","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","article-title":"Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3","volume":"137","author":"Chadwick","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2026.05.020_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102486","article-title":"In vivo base editing of Angptl3 via lipid nanoparticles to treat cardiovascular disease","volume":"36","author":"Khirallah","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.05.020_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100701","article-title":"Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond","volume":"19","author":"Safarova","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2023.12.001","article-title":"First in vivo base-editing trial shows promise","volume":"32","author":"Han","year":"2024","journal-title":"Mol. Ther. : J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.05.020_bib40","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1038\/s41467-021-23996-y","article-title":"Efficient precise in vivo base editing in adult dystrophic mice","volume":"12","author":"Xu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.05.020_bib41","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/nbt.3404","article-title":"Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition","volume":"33","author":"Kleinstiver","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41587-022-01410-2","article-title":"High-throughput continuous evolution of compact Cas9 variants targeting single-nucleotide-pyrimidine PAMs","volume":"41","author":"Huang","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib43","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.ymthe.2020.04.009","article-title":"BEON: A Functional Fluorescence Reporter for Quantification and Enrichment of Adenine Base-Editing Activity","volume":"28","author":"Wang","year":"2020","journal-title":"Mol. Ther. : J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.05.020_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.omtm.2018.01.004","article-title":"Target-Cell-Directed Bioengineering Approaches for Gene Therapy of Hemophilia A","volume":"9","author":"Brown","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.05.020_bib45","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s12933-024-02507-5","article-title":"ASGR1 deficiency improves atherosclerosis but alters liver metabolism in ApoE(-\/-) mice","volume":"23","author":"Svecla","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-023-02099-6","article-title":"ASGR1 deficiency diverts lipids toward adipose tissue but results in liver damage during obesity","volume":"23","author":"Svecla","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12916-023-02903-w","article-title":"Genetically mimicked effects of ASGR1 inhibitors on all-cause mortality and health outcomes: a drug-target Mendelian randomization study and a phenome-wide association study","volume":"21","author":"Yang","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.ymthe.2026.05.020_bib48","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41587-020-0491-6","article-title":"Directed evolution of adenine base editors with increased activity and therapeutic application","volume":"38","author":"Gaudelli","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib49","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41587-020-0562-8","article-title":"Author Correction: Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity","volume":"38","author":"Richter","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib50","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","article-title":"Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases","volume":"30","author":"Bae","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2026.05.020_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114111","article-title":"Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption","volume":"230","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ymthe.2026.05.020_bib52","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.020_bib53","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00418-009-0577-1","article-title":"Cellular organization of normal mouse liver: a histological, quantitative immunocytochemical, and fine structural analysis","volume":"131","author":"Baratta","year":"2009","journal-title":"Histochem. Cel Biol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.020_bib55","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.05.020_bib56","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1038\/s41467-023-37604-8","article-title":"Direct correction of haemoglobin E beta-thalassaemia using base editors","volume":"14","author":"Badat","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.05.020_bib57","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2026.05.020_bib58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib59","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/17474124.2019.1549988","article-title":"Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention","volume":"13","author":"Di Ciaula","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.24","article-title":"Gallstones","volume":"2","author":"Lammert","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2026.05.020_bib61","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.bi.51.070182.002531","article-title":"Carbohydrate-specific receptors of the liver","volume":"51","author":"Ashwell","year":"1982","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ymthe.2026.05.020_bib62","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1152\/physrev.1995.75.3.591","article-title":"The asialoglycoprotein receptor: relationships between structure, function, and expression","volume":"75","author":"Stockert","year":"1995","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ymthe.2026.05.020_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202409440","article-title":"Accessing Therapeutically-Relevant Multifunctional Antisense Oligonucleotide Conjugates Using Native Chemical Ligation","volume":"63","author":"Engelhardt","year":"2024","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ymthe.2026.05.020_bib64","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.020_bib65","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: First Approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2026.05.020_bib66","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: First Approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2026.05.020_bib67","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: First Approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2026.05.020_bib68","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S2468-1253(24)00237-1","article-title":"VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study","volume":"9","author":"Yuen","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2026.05.020_bib69","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/crispr.2019.0017","article-title":"BEAT: A Python Program to Quantify Base Editing from Sanger Sequencing","volume":"2","author":"Xu","year":"2019","journal-title":"CRISPR J."},{"key":"10.1016\/j.ymthe.2026.05.020_bib70","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","article-title":"CRISPResso2 provides accurate and rapid genome editing sequence analysis","volume":"37","author":"Clement","year":"2019","journal-title":"Nat. Biotechnol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T20:47:06Z","timestamp":1785962826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626004077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1525001626004077"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.020","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo base editing of Asgr1 reduces blood lipids in mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}